The combination of lenvatinib (Lenvima) plus everolimus was found to be safe and effective in patients with clear cell renal cell carcinoma (RCC) who had been treated with an immune checkpoint inhibitor in prior lines of therapy.1
These results were from an exploratory analysis of a phase 2 trial (NCT03173560) of lenvatinib at 2 different starting doses plus a set dose of everolimus following prior VEGF inhibitor therapy and were presented virtually at the 2021 Genitourinary Cancers Symposium.
“Because of changes to the treatment landscape, first-line treatment often includes immune checkpoint inhibitor (ICI) therapy, and therefore, it is important to examine the antitumor response and safety of lenvatinib [plus] everolimus in this patient subgroup,” the study investigators, who were led by Sumanta K. Pal, MD, wrote in their poster presentation.
Out of 343 patients enrolled in the…
